Lotan - Figure 23
Multicenter Evaluation of Urovysion in Surveillance of Patients with Bladder Cancer
FIG. 23: In a large multicenter evaluation of patients with bladder cancer, the UroVysion® FISH assay and surveillance was performed in 664 patients who had a normal cystoscopy result; patients with evidence of tumor or a positive cytology were excluded.[14]
Over a median follow-up of 26 months, 42% of the 664 patients had a recurrence. The interesting finding was that patients who had a positive UroVysion® FISH assay had a recurrence within 12.6 months, but if the assay was negative, the recurrence happened at close to 18 months. FISH positivity was associated with a recurrence in univariate but not multivariate analysis.
The issue here is what to do when a patient has a positive UroVysion® assay result and a normal cystoscopy. There is not much that can be done when the average recurrence happens 1 year later, other than to monitor the patient carefully, so it is difficult to make additional recommendations on treatment in this setting.
References
Seideman C, Canter D, Kim P, et al. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol. 2015;33:1309−13 https://doi.org/10.1007/s00345-014-1452-9
